ER-Associated Degradation (ERAD) Cross-Activation

Target: EIF2AK3 (PERK), EIF2S1 (eIF2α); HSPA5 (BiP), XBP1 Composite Score: 0.545 Price: $0.65▼11.0% Citation Quality: Pending Status: proposed
☰ Compare⚛ Collideinteract with this hypothesis
📄 Export → LaTeX
Select venue
arXiv Preprint NeurIPS Nature Methods PLOS ONE
🌐 Open in Overleaf →
📖 Export BibTeX
✓ All Quality Gates Passed
Evidence Strength Pending (0%)
0
Citations
1
Debates
4
Supporting
3
Opposing
Quality Report Card click to collapse
C+
Composite: 0.545
Top 58% of 1875 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
B+ Mech. Plausibility 15% 0.71 Top 34%
C Evidence Strength 15% 0.47 Top 70%
F Novelty 12% 0.00 Top 50%
F Feasibility 12% 0.00 Top 50%
F Impact 12% 0.00 Top 50%
F Druggability 10% 0.00 Top 50%
F Safety Profile 8% 0.00 Top 50%
F Competition 6% 0.00 Top 50%
F Data Availability 5% 0.00 Top 50%
F Reproducibility 5% 0.00 Top 50%
Evidence
4 supporting | 3 opposing
Citation quality: 0%
Debates
1 session A+
Avg quality: 1.00

From Analysis:

How does the intron-retained RNA isoform mechanistically reduce glucocerebrosidase protein levels and activity?

How does the intron-retained RNA isoform mechanistically reduce glucocerebrosidase protein levels and activity?

→ View full analysis & debate transcript

Description

Partial translation of intron-retained GBA transcripts produces misfolded peptide fragments that mislocalize to the ER membrane rather than entering the ER lumen, causing local ER stress. PERK dimerizes and auto-phosphorylates eIF2α, globally suppressing cap-dependent translation initiation. Since GBA translation requires efficient initiation due to its complex multi-domain structure, eIF2α-mediated repression disproportionately reduces GBA protein synthesis. ISRIB provides a direct pharmacological test of this mechanism.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["EIF2AK3 (PERK)
Kinase"] B["EIF2S1 (eIF2alpha)
Translation Initiation"] C["HSPA5 (BiP)
chaperone"] D["XBP1
Unfolded Protein Response"] E["ERAD
Cross-Activation"] F["Proteasomal
Clearance Deficit"] G["Synaptic
Protein Dysregulation"] H["Neurodegeneration
Proteostasis Failure"] A --> B B --> C C --> D D --> E E --> F F --> G G --> H style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

GTEx v10 Brain Expression

JSON

Median TPM across 13 brain regions for EIF2AK3 (PERK), EIF2S1 (eIF2α); HSPA5 (BiP), XBP1 from GTEx v10.

Cerebellar Hemisphere4.1 Cerebellum4.0 Spinal cord cervical c-13.4 Frontal Cortex BA92.1 Hypothalamus2.0 Substantia nigra1.9 Cortex1.9 Nucleus accumbens basal ganglia1.6 Hippocampus1.6 Caudate basal ganglia1.5 Anterior cingulate cortex BA241.5 Amygdala1.5 Putamen basal ganglia1.5median TPM (GTEx v10)

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.71 (15%) Evidence 0.47 (15%) Novelty 0.00 (12%) Feasibility 0.00 (12%) Impact 0.00 (12%) Druggability 0.00 (10%) Safety 0.00 (8%) Competition 0.00 (6%) Data Avail. 0.00 (5%) Reproducible 0.00 (5%) KG Connect 0.50 (8%) 0.545 composite
7 citations 7 with PMID Validation: 0% 4 supporting / 3 opposing
For (4)
No supporting evidence
No opposing evidence
(3) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
6
1
MECH 6CLIN 1GENE 0EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
PERK activation suppresses protein synthesis in Pa…SupportingMECH----PMID:34542589-
ER stress reduces GCase activity in neuron modelsSupportingMECH----PMID:30704899-
GBA enzyme requires precise ER folding and quality…SupportingMECH----PMID:35604718-
ISRIB (eIF2B activator) in Phase I trials for cogn…SupportingCLIN----PMID:05039082-
PERK activation requires substantial ER stress thr…OpposingMECH----PMID:31171707-
If PERK is activated, eIF2α phosphorylation suppre…OpposingMECH----PMID:34542589-
ER stress reducing GCase activity may reflect gene…OpposingMECH----PMID:30704899-
Legacy Card View — expandable citation cards

Supporting Evidence 4

PERK activation suppresses protein synthesis in Parkinson's disease models
ER stress reduces GCase activity in neuron models
GBA enzyme requires precise ER folding and quality control
ISRIB (eIF2B activator) in Phase I trials for cognitive disorders - safety profile partially established

Opposing Evidence 3

PERK activation requires substantial ER stress threshold unlikely achieved by low-abundance intron-retained tr…
PERK activation requires substantial ER stress threshold unlikely achieved by low-abundance intron-retained transcripts
If PERK is activated, eIF2α phosphorylation suppresses all cap-dependent translation, not selectively GBA
ER stress reducing GCase activity may reflect general folding impairment rather than specific mechanism
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-26 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Mechanistic Hypotheses: Intron-Retained GBA Isoform and Protein Reduction

The research question addresses how a specific intron-retaining transcript of GBA (glucosylceramidase, the gene mutated in Gaucher disease) leads to reduced protein levels and enzymatic activity—a phenomenon particularly relevant given that GBA haploinsufficiency is a major Parkinson's disease risk factor.

Hypothesis 1: Ribosome Stalling and Collision-Induced Translational Repression

Title: Cytoplasmic Intron-Retained GBA Transcripts Stall Ribosomes, Activating Collisional Quality Control That Glob

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

Critical Evaluation of GBA Intron-Retention Hypotheses

Hypothesis 1: Ribosome Stalling and Collision-Induced Translational Repression

Weaknesses and Challenges

  • Nuclear Retention Assumption: The hypothesis assumes intron-retained GBA transcripts "escape nuclear retention," but published evidence indicates the vast majority of intron-retained transcripts are efficiently nuclear-retained, particularly in neuronal cells (Bove et al., 2021; PMID: 33711246). Only a small fraction may escape, making the overall effect potentially negligible.
  • **Collision Sensor Specificit
  • 🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

    Practical Feasibility Assessment: GBA Intron-Retention Mechanisms

    Surviving Hypotheses

    Based on the critique revision, the hypotheses with sufficient mechanistic support to warrant drug development consideration are:

    | Rank | Hypothesis | Revised Confidence | Strategic Priority |
    |------|-----------|-------------------|-------------------|
    | 1 | RBP Sequestration (H6) | 0.58 | High — neuronal context, established targets |
    | 2 | Ribosome Stalling (H1) | 0.52 | High — measurable, actionable pathway |
    | 3 | SRP Interference (H7) | 0.52 | Moderate — signal peptide biology is

    Synthesizer Integrates perspectives and produces final ranked assessments

    {"ranked_hypotheses":[{"title":"Dominant-Negative Spliceosome Titration","description":"Intron-retained GBA transcripts sequester core spliceosomal components (U2AF65, SF3B1, PRPF8) and snRNPs, reducing the available pool for wild-type GBA pre-mRNA processing. This cis-trans interference causes inefficient removal of downstream introns, producing additional aberrant transcripts with PTCs that are degraded by NMD, establishing a positive feedback loop that progressively depletes mature GBA mRNA and protein. The mechanism explains why a minority aberrant isoform disproportionately affects prot

    Price History

    0.560.600.63 0.67 0.53 2026-04-252026-04-262026-04-27 Market PriceScoreevidencedebate 7 events
    7d Trend
    Stable
    7d Momentum
    ▼ 11.1%
    Volatility
    High
    0.0807
    Events (7d)
    7

    Clinical Trials (0)

    No clinical trials data available

    📚 Cited Papers (5)

    No extracted figures yet
    No extracted figures yet
    No extracted figures yet
    No extracted figures yet
    No extracted figures yet

    📅 Citation Freshness Audit

    Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

    No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

    📙 Related Wiki Pages (0)

    No wiki pages linked to this hypothesis yet.

    ࢐ Browse all wiki pages

    📓 Linked Notebooks (0)

    No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

    ⚔ Arena Performance

    No arena matches recorded yet. Browse Arenas
    → Browse all arenas & tournaments

    📊 Resource Economics & ROI

    Moderate Efficiency Resource Efficiency Score
    0.50
    32.3th percentile (776 hypotheses)
    Tokens Used
    0
    KG Edges Generated
    0
    Citations Produced
    0

    Cost Ratios

    Cost per KG Edge
    0.00 tokens
    Lower is better (baseline: 2000)
    Cost per Citation
    0.00 tokens
    Lower is better (baseline: 1000)
    Cost per Score Point
    0.00 tokens
    Tokens / composite_score

    Score Impact

    Efficiency Boost to Composite
    +0.050
    10% weight of efficiency score
    Adjusted Composite
    0.595

    How Economics Pricing Works

    Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

    High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

    Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

    Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

    📋 Reviews View all →

    Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

    💬 Discussion

    No DepMap CRISPR Chronos data found for EIF2AK3 (PERK), EIF2S1 (eIF2α); HSPA5 (BiP), XBP1.

    Run python3 scripts/backfill_hypothesis_depmap.py to populate.

    No curated ClinVar variants loaded for this hypothesis.

    Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

    🔍 Search ClinVar for EIF2AK3 (PERK), EIF2S1 (eIF2α); HSPA5 (BiP), XBP1 →
    Loading history…

    ⚖️ Governance History

    No governance decisions recorded for this hypothesis.

    Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

    Browse all governance decisions →

    KG Entities (75)

    ASO therapyASOsCap-dependent translationDICER1EIF2AK3 (PERK)EIF2S1 (eIF2α)EIF2S1 (eIF2α) phosphorylationELAVL1 (HuR)FMR1 (FMRP)FMRPGBAGBA ER targetingGBA haploinsufficiencyGBA intron dsRNAGBA intron retentionGBA intron retention clearanceGBA intron-retained transcriptGBA lysosomal deliveryGBA lysosomal targetingGBA mRNA

    Related Hypotheses

    No related hypotheses found

    Estimated Development

    Estimated Cost
    $0
    Timeline
    0 months

    🧪 Falsifiable Predictions (2)

    2 total 0 confirmed 0 falsified
    IF primary fibroblasts or iPSC-derived neurons carrying pathogenic intron-retained GBA transcripts are treated with ISRIB (200 nM, 4-24 hours), THEN GBA protein levels will increase by >30% relative to vehicle-treated cells, because ISRIB bypasses eIF2α-mediated translational repression to restore cap-dependent initiation of GBA mRNA.
    pending conf: 0.45
    Expected outcome: GBA protein abundance measured by quantitative western blot or targeted mass spectrometry will increase >30% in ISRIB-treated cells compared to vehicle controls within 24 hours of drug addition.
    Falsified by: GBA protein levels in ISRIB-treated cells remain within ±10% of vehicle control levels, indicating that translational repression of GBA is not rescued by eIF2B potentiation and the hypothesis is incorrect.
    Method: Human patient-derived fibroblasts or iPSC-derived neurons (carrying pathogenic GBA intron retention confirmed by RNA-seq, e.g., from Gaucher disease patients with splice-switching variants) treated with ISIBR (200 nM) or 0.1% DMSO vehicle for 4-24 hours, with GBA protein quantified by parallel reaction monitoring mass spectrometry or quantitative western blot normalized to loading control.
    IF HEK293T cells or patient-derived fibroblasts are transfected with PERK-targeting siRNA 48 hours prior to GBA intron-retention expression, THEN phospho-eIF2α levels will be reduced by >70% and GBA protein synthesis will be restored to levels comparable to non-stressed cells, because PERK signaling is the upstream trigger suppressing GBA translation.
    pending conf: 0.38
    Expected outcome: Phospho-eIF2α (SerS51) will be reduced >70% by western blot, and newly synthesized GBA protein measured by puromycin incorporation or S35-methionine pulse chase will increase to >80% of levels in cells without ER stress.
    Falsified by: Silencing PERK reduces eIF2α phosphorylation but GBA protein synthesis remains suppressed (>50% below baseline), indicating an eIF2α-independent translational block or that GBA mRNA itself is degraded, disproving the proposed mechanism.
    Method: HEK293T cells or patient-derived fibroblasts transfected with siGENOME SMARTpool PERK (EIF2AK3) siRNA or non-targeting control using Lipofectamine RNAiMAX; after 48 hours, ER stress induced by thapsigargin (1 μM, 2 hours) or endogenous intron-retained GBA expression, followed by phospho-eIF2α immunoblot and metabolic labeling of newly synthesized proteins via S35-cysteine/methionine pulse (15 min) with GBA immunoprecipitation and autoradiography or targeted proteomics.

    Knowledge Subgraph (48 edges)

    activates (4)

    ZNF598ribosome collisionGIGYF2ribosome collisionribosome stallingZNF598/GIGYF2 collision sensorsribosome collisionribosome-associated quality control

    activates collisional sensor (1)

    GBA intron-retained transcriptZNF598

    associated with (1)

    GIGYF2 mutationsParkinsonism

    causal extracted (1)

    sess_SDA-2026-04-26-gap-pubmed-20260412-094853-199f4f1bprocessed

    causes (5)

    ribosome stallingRQC activationintron retentionspliceosomal component sequestrationRBP sequestrationGBA mRNA decayintron retentioncytoplasmic export of aberrant transcriptspositive feedback loopGBA protein depletion

    disrupts (1)

    TARDBP (TDP-43) aggregationGBA intron retention clearance

    inhibits (7)

    TDP-43 aggregationGBA intron retention clearanceTDP-43 aggregationintron retention clearanceintron-retained GBA transcriptswild-type GBA pre-mRNA processingZNF598/GIGYF2 activationglobal translationaberrant translation initiationSRP recruitment to normal transcripts
    ▸ Show 2 more

    lysosomal trafficking chaperone (1)

    SCARB2 (LIMP-2)GBA protein

    modulates (3)

    SRP bindingwild-type GBA ER targetingsplicing modulatorsGBA intron retentionsplicing modulatorsspliceosome function

    phosphorylates (1)

    EIF2AK3 (PERK)EIF2S1 (eIF2α)

    processes into siRNA (1)

    DICER1GBA intron dsRNA

    protective against (1)

    LIMP-2 enhancementGBA protein levels

    recognizes for ER targeting (1)

    SRP54GBA signal peptide

    recruits (1)

    GBA intron-retained transcriptGIGYF2

    regulates (4)

    LIMP-2GBA lysosomal targetingFMRPGBA mRNASCARB2GBA lysosomal deliveryFMRPGBA mRNA translation

    regulates translation (1)

    FMR1 (FMRP)GBA mRNA

    requires for nuclear export (1)

    GBA wild-type mRNANXF1 (TAP)

    risk factor for (2)

    GBAParkinson's diseaseGBA haploinsufficiencyParkinson's disease

    sequesters (4)

    GBA intron-retained transcriptSF3B1GBA intron-retained transcriptU2AF2GBA intron-retained transcriptPRPF8intron-retained GBA transcriptsspliceosomal components

    stabilizes (1)

    ELAVL1 (HuR)GBA mRNA

    suppresses (1)

    EIF2S1 (eIF2α) phosphorylationCap-dependent translation

    therapeutic target for (5)

    TDP-43GBA-PDASOsintron-retained GBAASO therapyintron-retained GBA transcriptsnusinersen/inotersenintronic targetsTDP-43 ASO programsTDP-43 aggregation

    Mechanism Pathway for EIF2AK3 (PERK), EIF2S1 (eIF2α); HSPA5 (BiP), XBP1

    Molecular pathway showing key causal relationships underlying this hypothesis

    graph TD
        GBA["GBA"] -->|risk factor for| Parkinson_s_disease["Parkinson's disease"]
        LIMP_2["LIMP-2"] -->|regulates| GBA_lysosomal_targeting["GBA lysosomal targeting"]
        GBA_haploinsufficiency["GBA haploinsufficiency"] -->|risk factor for| Parkinson_s_disease_1["Parkinson's disease"]
        TDP_43_aggregation["TDP-43 aggregation"] -.->|inhibits| intron_retention_clearanc["intron retention clearance"]
        FMRP["FMRP"] -->|regulates| GBA_mRNA_translation["GBA mRNA translation"]
        nusinersen_inotersen["nusinersen/inotersen"] -->|therapeutic target| intronic_targets["intronic targets"]
        TDP_43_ASO_programs["TDP-43 ASO programs"] -->|therapeutic target| TDP_43_aggregation_2["TDP-43 aggregation"]
        TDP_43["TDP-43"] -->|therapeutic target| GBA_PD["GBA-PD"]
        TDP_43_aggregation_3["TDP-43 aggregation"] -.->|inhibits| GBA_intron_retention_clea["GBA intron retention clearance"]
        ZNF598["ZNF598"] -->|activates| ribosome_collision["ribosome collision"]
        GIGYF2["GIGYF2"] -->|activates| ribosome_collision_4["ribosome collision"]
        FMRP_5["FMRP"] -->|regulates| GBA_mRNA["GBA mRNA"]
        style GBA fill:#ce93d8,stroke:#333,color:#000
        style Parkinson_s_disease fill:#ef5350,stroke:#333,color:#000
        style LIMP_2 fill:#4fc3f7,stroke:#333,color:#000
        style GBA_lysosomal_targeting fill:#4fc3f7,stroke:#333,color:#000
        style GBA_haploinsufficiency fill:#4fc3f7,stroke:#333,color:#000
        style Parkinson_s_disease_1 fill:#ef5350,stroke:#333,color:#000
        style TDP_43_aggregation fill:#4fc3f7,stroke:#333,color:#000
        style intron_retention_clearanc fill:#4fc3f7,stroke:#333,color:#000
        style FMRP fill:#4fc3f7,stroke:#333,color:#000
        style GBA_mRNA_translation fill:#4fc3f7,stroke:#333,color:#000
        style nusinersen_inotersen fill:#4fc3f7,stroke:#333,color:#000
        style intronic_targets fill:#ce93d8,stroke:#333,color:#000
        style TDP_43_ASO_programs fill:#4fc3f7,stroke:#333,color:#000
        style TDP_43_aggregation_2 fill:#4fc3f7,stroke:#333,color:#000
        style TDP_43 fill:#4fc3f7,stroke:#333,color:#000
        style GBA_PD fill:#ef5350,stroke:#333,color:#000
        style TDP_43_aggregation_3 fill:#4fc3f7,stroke:#333,color:#000
        style GBA_intron_retention_clea fill:#4fc3f7,stroke:#333,color:#000
        style ZNF598 fill:#4fc3f7,stroke:#333,color:#000
        style ribosome_collision fill:#4fc3f7,stroke:#333,color:#000
        style GIGYF2 fill:#4fc3f7,stroke:#333,color:#000
        style ribosome_collision_4 fill:#4fc3f7,stroke:#333,color:#000
        style FMRP_5 fill:#4fc3f7,stroke:#333,color:#000
        style GBA_mRNA fill:#4fc3f7,stroke:#333,color:#000

    3D Protein Structure

    🧬 EIF2AK3 — Search for structure Click to search RCSB PDB
    🔍 Searching RCSB PDB for EIF2AK3 structures...
    Querying Protein Data Bank API

    Source Analysis

    How does the intron-retained RNA isoform mechanistically reduce glucocerebrosidase protein levels and activity?

    neurodegeneration | 2026-04-26 | completed

    Community Feedback

    0 0 upvotes · 0 downvotes
    💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

    No comments yet. Be the first to comment!

    View all feedback (JSON)

    Same Analysis (5)

    Dominant-Negative Spliceosome Titration
    Score: 0.65 · U2AF2, SF3B1, PRPF8; splicing snRNPs
    RNA-Binding Protein Sequestration and 3′UTR Dysregulation
    Score: 0.62 · ELAVL1 (HuR), FMR1 (FMRP), TARDBP (TDP-43); GW182 (TNRC6A)
    Ribosome Stalling and Collision-Induced Translational Repression
    Score: 0.62 · GBA mRNA; ZNF598, GIGYF2, RQC components
    Co-translational ER Targeting Defect and Lysosomal Delivery Failure
    Score: 0.55 · SRP54, SRP68, SRP72 (SRP components); SCARB2 (LIMP-2)
    Nuclear Export Sequestration and Cytoplasmic Depletion
    Score: 0.48 · NXF1 (TAP), THOC4 (AlyREF), DDX39B (UAP56); PHAX
    → View all analysis hypotheses
    Public annotations (0)Annotate on Hypothes.is →
    No public annotations yet.